Whisk#s AI-Powered Culinary Coach Named as Winner of Ascensia Diabetes Challenge

Food and Healthcare Press Releases Monday June 25, 2018 08:55
Basel, Switzerland and Florida, USA--25 Jun--PRNewswire/InfoQuest

Today, at the American Diabetes Association's 78th Scientific Sessions in Orlando, Florida, Ascensia Diabetes Care has revealed that UK-based Whisk have been selected as the winner of the Ascensia Diabetes Challenge, a global innovation competition that set out to find digital solutions to support type 2 diabetes management.

(Logo: https://mma.prnewswire.com/media/709497/Ascensia_Diabetes_Challenge_Logo.jpg )
(Photo: https://mma.prnewswire.com/media/709496/Ascensia_Diabetes_Integration.jpg )

Whisk's winning innovation is a Culinary Coach that uses artificial intelligence (AI) to provide personalized food recommendations based on flavor preferences and food avoidance, that will be expanded to use blood glucose data for people with diabetes. Later today, Whisk will be presenting their winning solution to the diabetes community for the first time at the 2018 DiabetesMine D-Data Exchange Event in Orlando.

The Whisk platform is an AI-powered nutrition platform that currently enables users to browse recipes based on factors including their personal taste preferences, time constraints, budgets, weather and dietary restrictions or allergies. Once a user adds a recipe to their meal plan, it can be automatically added to an online shopping cart at some of the world's leading grocery retailers, seamlessly allowing them to buy ingredients.

As winner of the challenge, Whisk plan to create a personalized food experience for people with type 2 diabetes that will learn from their blood glucose readings and make food recommendations that are more tailored to their own diabetes. Using readings from Ascensia's blood glucose monitoring systems, the AI will learn how the user's blood glucose readings react to specific foods and recipes, allowing them to build a tailored meal plan for their diabetes that can help to keep their blood glucose in range. The Culinary Coach for diabetes will start by providing personalized recipe recommendations, and will in the future develop to suggest convenience foods and restaurant options.

Michael Kloss, CEO and President of Ascensia Diabetes Care, said: "Nutrition and food selection is a huge component of type 2 diabetes management. The panel of judges and I were hugely impressed by Whisk's current tool and how they plan to develop it for people with type 2 diabetes. By helping people with type 2 diabetes find personalized and tailored meal recommendations that are based on their own blood glucose data and food preferences, we have the potential to empower millions of people with type 2 diabetes to make healthier food choices that they will enjoy."

Whisk's solution was selected from 116 entries that were submitted to the challenge from 25 countries and they will receive a cash prize of EUR100,000 to build and pilot this exciting new service for people with type 2 diabetes, working closely with Ascensia Diabetes Care to bring it to patients.

Whisk's core technology uses extensive food ontology known as the Food Genome(TM), that incorporates and understands macro and micro-nutritional data, flavor compounds, store availability, price and promotions. Whisk is currently available in the US, UK and Australia, powering half a million shopping lists every month at grocery retailers including Walmart, Tesco and Amazon Fresh.

Nick Holzherr, Whisk Founder and CEO, said: "We are absolutely delighted to have been chosen as the winner of the Ascensia Diabetes Challenge. Type 2 diabetes has reached epidemic levels in recent years, and at Whisk we are excited to be building a solution that we feel can help support these patients to make lasting lifestyle changes. We hope that through our work with Ascensia Diabetes Care, we can help to change the way this condition is managed."

The competition also awarded two runners-up prizes. US-based Qstream were awarded a runner-up prize for their mobile learning platform that combines a concept known as spaced education with engaging game mechanics. This platform is designed to encourage meaningful behavior change and has been proven in a recent randomized trial to generate sustained and meaningful reductions in HbA1c in people with diabetes.1 xBird, a Germany-based medical artificial intelligence software company was also named as a runner-up. Their software analyzes micro-movements, collected by smartphones and wearables, and cross references them with historical blood glucose data, with the aim of being able to predict and detect potential hypo- and hyperglycemic events. Both runners-up will receive a cash prize of EUR30,000 to further develop their solutions.

Walk With Path were also recognized for their highly innovative active insole for people with peripheral neuropathy due to diabetes. Their insole provides vibrational feedback during walking that can be tracked via an app and is designed to help people achieve better balance, thereby reducing the risk of falls. Ascensia will support Walk with Path to conduct a proof of concept study in patients with diabetes.

Michael added, "We are very excited to partner with such high quality digital solutions that could help revolutionize type 2 diabetes management. These winning solutions highlight the exciting times we are now entering in the world of digital health and how technological advances and digital capabilities can play a massive part in meeting an urgent area of unmet need."

For further information on the Ascensia Diabetes Challenge, the judges and judging criteria, please visit: https://ascensiadiabeteschallenge.com .
For more information, please contact:
Joseph Delahunty, VP, Global Head of Communications
Ascensia Diabetes Care
E-mail: joseph.delahunty@ascensia.com
References
1. Kerfoot BP et al. Diabetes Care (2017) 40:1218-1225
Source: Ascensia Diabetes Care

Latest Press Release

Michel Orsinger Assumes Role as Chairman of Limacorporate#s Advisory Board

LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate's Advisory Board, will assume the role of Chairman of the Board. Michel joined the Advisory Board mid-2017 following a long and successful global career in...

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the...

APEC#s Rare Disease Action Plan Sets Precedent to Integrate Rare Disease Care by 2025

- Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF) Rare Disease Network comprises Rare Disease International, Queensland University of Technology and Shire (representing as industry co-chair). - Aims to define, diagnose and...

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Ascensia Diabetes Care Highlights the Support That Families Provide for People With Diabetes To Mark World Diabetes Day 2018

Today, Ascensia Diabetes Care, a global leading diabetes care company, launched their campaign for World Diabetes Day 2018 to celebrate the important role of families for people with diabetes. They are publishing 38 online artworks that tell the stories...

Related Topics